Category: Hematology

AVERT Trial: Apixaban to Prevent VTE in Patients with Cancer

2018, Apixaban to Prevent Venous Thromboembolism in Patients with Cancer, NEJM The AVERT trial evaluated the use of apixaban for preventing venous thromboemboli such as deep venous thrombosis and pulmonary embolism in patients with cancer who were scheduled to start chemotherapy. These patients were at high risk of VTE based on the Khorana score. The point..

Read more